AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR2019

AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR

Shots:

  • The P-III SELECT EARLY & SELECT-COMPARE study results involve assessing of Upadacitinib (15mg/30mg,qd) as monothx. & Upadacitinib + MTX (15mg, qd) vs MTX & adalimumab + MTX in patients with rheumatoid arthritis respectively
  • The P-III SELECT EARLY & SELECT-COMPARE study results: @48wks. improvement in symptoms of rheumatoid arthritis measured by ACR20/50; maintain clinical remission based on (DAS28-CRP) <2.6; presented at EULAR
  • Upadacitinib is JAK1-selective inhibitor, being evaluated in multiple P-III clinical studies for psoriatic arthritis, Crohn’s disease, atopic dermatitis, and ulcerative colitis and being investigated to treat ankylosing spondylitis and giant cell arteritis

Click here to read full press release/ article | Ref: AbbVie | Image: Punktlandung